Actively Recruiting
Evaluating DFL24498 Eye Drops Compared to Placebo for Atopic Keratoconjunctivitis Treatment in Adults and Children
Led by Dompé Farmaceutici S.p.A · Updated on 2026-09-21
153
Participants Needed
19
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of DFL24498 eye drops compared to a placebo vehicle in people aged 10 to 65 with atopic keratoconjunctivitis AKC, a condition affecting the eyes. This phase 3 study is randomized, double-masked, and conducted at multiple centers. It includes two groups adults and children, with adults equally assigned to receive DFL24498 or placebo, while children are more likely to receive DFL24498. The study has three parts a washout period lasting about one week before treatment starts, a 12-week treatment period where participants receive either DFL24498 or placebo eye drops in both eyes, and a follow-up period from weeks 13 to 16. Rescue medication with dexamethasone sodium phosphate may be given if needed during the study. Participants are monitored throughout these stages. During the study, participants will have their eye symptoms such as itching, redness, and corneal damage measured at various times including baseline, week 4, week 6, week 8, week 12, and week 16. Quality of life and global impression of change assessments are done in adults. Safety is closely monitored, including any side effects or adverse events, with vision and eye pressure also evaluated. The main outcome is the change in eye itching at week 6 compared to the start of treatment.
CONDITIONS
Brief Title
An Efficacy and Safety Study of DFL24498 in the Treatment of AKC
Research Team
D
Dompé farmaceutici S.p.A. Via Santa Lucia, 6, 20122 Milan (MI)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here